Home » Topics » Regulatory » EMA

EMA
RSS

AstraZeneca receives positive CHMP opinion for vandetanib

Nov. 21, 2011

No Comments

EMA accepts Nuedexta MAA for filing

Nov. 18, 2011

No Comments

AMT's gene therapy for hemophilia B given orphan drug status in Europe

Nov. 16, 2011

No Comments

FDA and EMA accept Astellas' submissions for mirabegron

Nov. 15, 2011

No Comments

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

Nov. 15, 2011

No Comments

EC withdraws marketing authorization for Ablavar

Nov. 14, 2011

No Comments

Novartis presents key developments of third quarter 2011

Nov. 11, 2011

No Comments

Discovery Labs' lucinactant gains European orphan drug status

Nov. 4, 2011

No Comments

European orphan drug status for Celldex Therapeutics' rindopepimut

Nov. 2, 2011

No Comments

Amsterdam Molecular Therapeutics announces restructuring

Oct. 31, 2011

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

EMA
RSS

AstraZeneca receives positive CHMP opinion for vandetanib

EMA accepts Nuedexta MAA for filing

AMT's gene therapy for hemophilia B given orphan drug status in Europe

FDA and EMA accept Astellas' submissions for mirabegron

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

EC withdraws marketing authorization for Ablavar

Novartis presents key developments of third quarter 2011

Discovery Labs' lucinactant gains European orphan drug status

European orphan drug status for Celldex Therapeutics' rindopepimut

Amsterdam Molecular Therapeutics announces restructuring

Today's news in brief

Today's news in brief

In muscular dystrophies, gene therapies race the clock

Bridgebio, with FDA approval, faces Pfizer in ATTR

Phase III AMD miss leaves BLA Outlook same with bevacizumab

EMA RSS

EMA
RSS